tiprankstipranks
Trending News
More News >
SAB Biotherapeutics (SABS)
NASDAQ:SABS
US Market

SAB Biotherapeutics (SABS) Income Statement

Compare
185 Followers

SAB Biotherapeutics Income Statement

Last quarter (Q3 2025), SAB Biotherapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, SAB Biotherapeutics's net income was $5.34M. See SAB Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 1.32M$ 2.24M$ 23.90M$ 60.88M$ 55.24M
Gross Profit
$ -3.47M$ -1.51M$ 20.61M$ 59.22M$ 55.24M
Operating Expenses
$ 39.44M$ 36.57M$ 49.53M$ 72.62M$ 34.68M
Depreciation and Amortization
$ 4.79M$ 3.75M$ 3.29M$ 1.65M$ 548.18K
EBITDA
$ -28.99M$ -38.13M$ -15.12M$ -15.20M$ 21.14M
Operating Income
$ -42.91M$ -38.08M$ -28.92M$ -13.39M$ 20.56M
Other Income/Expenses
$ 8.81M$ -4.12M$ 10.20M$ -3.75M$ -439.00K
Pretax Income
$ -34.11M$ -42.19M$ -18.72M$ -17.14M$ 20.12M
Net Income
$ -34.11M$ -42.19M$ -18.74M$ -17.14M$ 20.12M
Per Share Metrics
Basic EPS
$ -3.68$ -7.64$ -4.31$ -3.94$ 4.63
Diluted EPS
$ -3.68$ -7.64$ -4.31$ -6.30$ 7.45
Weighted Average Shares Outstanding
9.26M 5.52M 4.35M 4.35M 4.35M
Weighted Average Shares Outstanding (Diluted)
9.26M 5.52M 4.35M 2.73M 2.70M
Currency in USD

SAB Biotherapeutics Earnings and Revenue History